Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Verge Analytics Inc. (Verge Genomics)
Headquarters: San Francisco, CA, United States of America
Website: http://www.vergegenomics.com...
Year Founded: 2015
Status: Private
BioCentury | Oct 2, 2024
Management Tracks
IGM names Mary Beth Harler CEO as it prioritizes T cell engagers
Plus: Ken Mills becomes CEO of Tagworks, and updates from AstronauTx, Trevi, Thrive and Madrigal
BioCentury | Feb 9, 2024
Product Development
Getting the most out of digital endpoints: case studies from Verge’s CMO
Perspectives from Diego Cadavid on Verge’s digital-first Phase Ib strategy for ALS, and on building a pivotal endpoint using an Xbox sensor
BioCentury | Feb 10, 2023
Discovery & Translation
Targeting PIKFYVE and SYF2 for ALS; plus new protein degraders and more
BioCentury's roundup of translational news
BioCentury | Dec 7, 2022
Management Tracks
Bill Meury to lead Karuna
Plus: Moore to head Roche Diagnostics North America division, and updates from Agios, Verge, LifeMine and more
BioCentury | Oct 17, 2022
Management Tracks
Baranowski becomes CEO at Avalyn
Plus new CMO at Ankyra as Kaufman becomes CEO, and updates from Verge, Zentalis, Aviceda and more
BioCentury | Feb 9, 2022
Management Tracks
Biogen’s Friedl-Naderer joins Vir as CBO
Plus Sandrock joins board at Verge, and updates from Simcere, OnKure, Glaukos and more
BioCentury | Dec 17, 2021
Finance
Verge prepares for clinical debut with strategics in $98M series B
Financing will also help expand the neuro company’s AI capabilities to include biomarker discovery, patient enrichment
BioCentury | Jul 10, 2021
Translation in Brief
Host genes associated with COVID susceptibility; plus Sana, Pfizer, Verge, Seelos and Pathios
BioCentury’s roundup of translational news
BioCentury | Jul 9, 2021
Deals
July 8 Quick Takes: F-Star STINGs AZ; plus Q1 PDUFA date for tezepelumab, Verge-Lilly, Oncopeptides, Adjuvant-
AstraZeneca plc (LSE:AZN; NYSE:AZN) licensed preclinical STING inhibitors from F-Star Therapeutics Inc. (NASDAQ:FSTX), adding the pharma to a small group of companies exploring the cancer target for
BioCentury | May 8, 2021
Management Tracks
Turnstone announces Burgess’ move to executive chairman alongside pair of promotions; plus Fulgent, Centene FDS, Akouos and more
Turnstone Biologics Inc. President of R&D Mike Burgess will become executive chairman of R&D. The cancer immunotherapy company also promoted José Otero to CTO from SVP of
Items per page:
1 - 10 of 18